Shares of Senseonics Holdings Inc (NYSEAMERICAN:SENS) have been assigned a consensus recommendation of “Hold” from the six analysts that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $6.00.
Separately, Zacks Investment Research lowered shares of Senseonics from a “hold” rating to a “sell” rating in a research report on Saturday, May 11th.
Shares of SENS traded up $0.08 during mid-day trading on Friday, reaching $2.09. 18,368 shares of the stock traded hands, compared to its average volume of 1,685,082. Senseonics has a 1 year low of $1.74 and a 1 year high of $5.29.
A number of institutional investors have recently bought and sold shares of the business. Marshall Wace North America L.P. bought a new stake in Senseonics in the first quarter worth $118,000. Marshall Wace LLP bought a new stake in Senseonics in the first quarter worth $272,000. Sio Capital Management LLC lifted its stake in Senseonics by 15.6% in the first quarter. Sio Capital Management LLC now owns 554,858 shares of the company’s stock worth $1,359,000 after purchasing an additional 75,000 shares during the last quarter. Man Group plc lifted its stake in Senseonics by 83.3% in the first quarter. Man Group plc now owns 68,200 shares of the company’s stock worth $167,000 after purchasing an additional 31,000 shares during the last quarter. Finally, Jefferies Group LLC bought a new position in shares of Senseonics during the first quarter valued at about $125,000. 30.66% of the stock is owned by institutional investors and hedge funds.
Senseonics Company Profile
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Featured Article: Fundamental Analysis and Individual Investors
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.